Recent Advances in Immunotherapy and Molecular Targeted Therapy for Gastric Cancer

Figures & data

Figure 1. Overview and the results of important gastric cancer clinical trials.

CAPOX: Capecitabine + oxaliplatin; CPS: Combined positive score; FOLFOX: 5-fluorouracil + leucovorin + oxaliplatin; FP: 5-fluorouracil + Cisplatin; Nivo: Nivolumab; OS: Overall survival; PFS: Progression-free survival; PD: Progressive disease; SOX: tegafur/gimeracil/oteracil potassium + oxaliplatin.

Table 1. This table shows ongoing pivotal clinical trials of anti-PD-1/PD-L1 therapies for gastric cancer.

Clinical trial	Phase	Line	Region	Patient selection	Regimen	Primary end point	Result
Attraction-6	III	1	Global	All (HER2-)	Nivo + Ipi + SOX/CAPOX SOX/CAPOX	OS	Ongoing
MAHOGANY	II/III	1	Global	HER2+	Margetuximab + Retifanlimab Margetuximab + Retifanlimab + CAPOX/FOLFOX Margetuximab + Tebotelimab + CAPOX/FOLFOX Margetuximab + CAPOX/FOLFOX Tmab + CAPOX/FOLFOX	OS	Ongoing
LEAP-015	III	1	Global	All (HER2-)	Pembo + Lenva + CAPOX/FOLFOX CAPOX/FOLFOX	OS/PFS	Ongoing

CAPOX: Capecitabine + oxaliplatin; FOLFOX: 5-FU + leucovorin + oxaliplatin; Ipi: Ipilimumab; Lenva: Lenvatinib; Nivo: Nivolumab; OS: Overall survival; PFS: Progression-free survival; Pembro: Pembrolizumab; SOX: Tegafur/gimeracil/oteracil potassium + oxaliplatin; Tmab: Trastuzumab.

Figure 2. Recommended chemotherapy regimens for AGC.

Recommended regimens are listed for each line of treatment in the Japanese guidelines. Red letters are ICI.

CDDP: Cisplatin; CAPOX: Capecitabine + oxaliplatin; FOLFOX: 5-FU + leucovorin + oxaliplatin; IRI: Irinotecan; PTX: Paclitaxel; RAM: Ramucirumab; Tmab: Trastuzumab; FTD/TPI: Trifluridine/tipiracil; S-1: Tegafur/gimeracil/oteracil potassium; SOX: Tegafur/gimeracil/oteracil potassium + oxaliplatin; T-DXd: Trastuzumab deruxtecan.

*This regimen is only available in USA.